Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis

NCT02474069 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

772

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate to Severe Plaque-type Psoriasis

Interventions

DRUG: Secukinumab

Sponsor

Novartis Pharmaceuticals